CA2085367A1 - Transactivateurs du vih servant a traiter le sida - Google Patents

Transactivateurs du vih servant a traiter le sida

Info

Publication number: CA2085367A1
Authority: CA; Canada
Prior art keywords: human; neomycin; poly; hydroxybenzyl; hiv
Prior art date: 1990-07-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002085367A

Other languages

English (en)

Inventor

William G. Tarpley

Roman P. Holysz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmacia and Upjohn Co

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-07-30

Filing date

1991-07-16

Publication date

1992-01-31

1991-07-16 Application filed by Individual filed Critical Individual

1992-01-31 Publication of CA2085367A1 publication Critical patent/CA2085367A1/fr

Status Abandoned legal-status Critical Current

Links

PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims abstract description 22
229960003704 framycetin Drugs 0.000 claims abstract description 22
150000003839 salts Chemical class 0.000 claims abstract description 10
150000004677 hydrates Chemical class 0.000 claims abstract description 8
150000001875 compounds Chemical class 0.000 claims description 23
238000000034 method Methods 0.000 claims description 21
208000030507 AIDS Diseases 0.000 claims description 12
241001430294 unidentified retrovirus Species 0.000 claims description 9
230000005764 inhibitory process Effects 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
230000010076 replication Effects 0.000 claims description 4
208000031886 HIV Infections Diseases 0.000 claims description 3
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
238000007910 systemic administration Methods 0.000 claims 2
241000725303 Human immunodeficiency virus Species 0.000 abstract description 22
241000282412 Homo Species 0.000 abstract description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
239000000203 mixture Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000000243 solution Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 5
229960002555 zidovudine Drugs 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
210000005259 peripheral blood Anatomy 0.000 description 4
239000011886 peripheral blood Substances 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
208000005384 Pneumocystis Pneumonia Diseases 0.000 description 3
206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
201000000317 pneumocystosis Diseases 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
241000220479 Acacia Species 0.000 description 2
241000222122 Candida albicans Species 0.000 description 2
206010007134 Candida infections Diseases 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010020144 Histoplasmosis disseminated Diseases 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
239000005909 Kieselgur Substances 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
-1 Neomycin B Schiff base Chemical class 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
239000008135 aqueous vehicle Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
238000009835 boiling Methods 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
201000003984 candidiasis Diseases 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000007788 liquid Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000003182 parenteral nutrition solution Substances 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000237858 Gastropoda Species 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229910019020 PtO2 Inorganic materials 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000012262 resinous product Substances 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
- C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
- C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
- C07H15/228—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings
- C07H15/232—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings with at least three saccharide radicals in the molecule, e.g. lividomycin, neomycin, paromomycin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002085367A 1990-07-30 1991-07-16 Transactivateurs du vih servant a traiter le sida Abandoned CA2085367A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55985190A	1990-07-30	1990-07-30
US559,851		1990-07-30

Publications (1)

Publication Number	Publication Date
CA2085367A1 true CA2085367A1 (fr)	1992-01-31

Family

ID=24235298

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002085367A Abandoned CA2085367A1 (fr)	1990-07-30	1991-07-16	Transactivateurs du vih servant a traiter le sida

Country Status (5)

Country	Link
EP (1)	EP0541597A1 (fr)
JP (1)	JPH05509306A (fr)
AU (1)	AU640511B2 (fr)
CA (1)	CA2085367A1 (fr)
WO (1)	WO1992002530A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08502966A (ja) *	1992-10-23	1996-04-02	ユニバーシティー・オブ・マサチューセッツ・メディカル・センター	Ｒｎａ／リガンド結合の低分子抑制
US5534408A (en) *	1993-09-24	1996-07-09	University Of Massachusetts Medical Center	2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
BR0209482A (pt) *	2001-05-10	2007-01-02	Wyeth Corp	composição e método para aumento da densidade celular em culturas de células infectadas com lentivìrus
US20050143328A1 (en) *	2003-10-31	2005-06-30	Steele Philip M.	Composition and treatment for envelope virus infections
WO2006052930A1 (fr)	2004-11-05	2006-05-18	Isis Pharmaceuticals, Inc.	Composes antimicrobiens de 2-desoxystreptamine
WO2007028012A2 (fr) *	2005-09-01	2007-03-08	Isis Pharmaceuticals, Inc.	Analogues d'aminoglycosides 4,5-substitues 6'-modifies antibacteriens
CA2632968A1 (fr)	2005-12-02	2007-06-07	Isis Pharmaceuticals, Inc.	Analogues d'aminoglycoside 4,5-substitues antibacteriens comportant plusieurs substituants
WO2010030704A2 (fr)	2008-09-10	2010-03-18	Achaogen, Inc.	Analogues d’aminoglycosides antibactériens
WO2010030690A1 (fr)	2008-09-10	2010-03-18	Isis Pharmaceuticals, Inc.	Analogues d'aminoglycosides 4,6-substitués et modifiés aux positions 6',6" et 1 possédant une activité antibactérienne
WO2010042851A1 (fr)	2008-10-09	2010-04-15	Achaogen, Inc.	Analogues d’aminoglycoside antibactériens
WO2010042850A1 (fr)	2008-10-09	2010-04-15	Achaogen, Inc.	Analogues d'aminoglycoside antibactériens
MX2012004036A (es)	2009-10-09	2012-06-27	Achaogen Inc	Analogos de aminoglicosidos antibacterianos.
AR083879A1 (es)	2010-11-17	2013-03-27	Achaogen Inc	Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos

1991
- 1991-07-16 AU AU82300/91A patent/AU640511B2/en not_active Ceased
- 1991-07-16 WO PCT/US1991/004849 patent/WO1992002530A1/fr not_active Ceased
- 1991-07-16 JP JP3512462A patent/JPH05509306A/ja active Pending
- 1991-07-16 CA CA002085367A patent/CA2085367A1/fr not_active Abandoned
- 1991-07-16 EP EP91913197A patent/EP0541597A1/fr not_active Ceased

Also Published As

Publication number	Publication date
AU8230091A (en)	1992-03-02
AU640511B2 (en)	1993-08-26
EP0541597A1 (fr)	1993-05-19
WO1992002530A1 (fr)	1992-02-20
JPH05509306A (ja)	1993-12-22

Legal Events

Date	Code	Title	Description
1998-07-16	FZDE	Discontinued
2022-09-10	FZDE	Discontinued	Effective date: 19980716

Publication	Publication Date	Title
AU716821B2 (en)	2000-03-09	Method to improve the biological and antiviral activity of protease inhibitors
WO1989007939A2 (fr)	1989-09-08	Coumarines permettant d'inhiber la transcriptase inverse chez les etres humains
UA125892C2 (uk)	2022-06-29	Інгібітор кінази aurora а для застосування в лікуванні нейробластоми
CA2085367A1 (fr)	1992-01-31	Transactivateurs du vih servant a traiter le sida
CN107281210B (zh)	2022-09-16	阿奇霉素在抗冠状病毒感染中的应用
DK164392B (da)	1992-06-22	Anvendelse af 3'-azido-3'-desoxythymidin til fremstilling af et laegemiddel til behandling af eller profylakse for en human retrovirusinfektion
DK169657B1 (da)	1995-01-09	Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider
CA2063417C (fr)	2000-12-12	Composition antivirale
CS182991A3 (en)	1992-04-15	Aminobenzodiazepines, process of their preparation and medicaments based thereon
US4835140A (en)	1989-05-30	Method for treating pneumocystis carinii pneumonia patients with clindamycin and primaquine
JP3237836B2 (ja)	2001-12-10	抗ウイルス医薬組成物
TW469132B (en)	2001-12-21	Antiviral combinations
US5545632A (en)	1996-08-13	Method of treating retroviral disease
DE68914990T2 (de)	1994-08-11	Verfahren zur inhibierung der wirkung des menschlichen immunschwäche-virus (hiv) in vivo.
US5519028A (en)	1996-05-21	Antiviral preparations
EP0914824A1 (fr)	1999-05-12	Medicament de prevention et de traitement des infections virales
US5541212A (en)	1996-07-30	Use of cimetidine for the control of retrovirus infections
TWI246424B (en)	2006-01-01	Use of 2-imidazolyl-substituted carbinols for the production of a medicament for the treatment or prophylaxis of diseases caused by ischemic conditions
US5534523A (en)	1996-07-09	Anti-aids virus composition
DE4320597A1 (de)	1995-01-05	Verwendung von Polyphosphaten zur antiviralen Therapie und als Immunmodulatoren
Derry et al.	1988	Agranulocytosis associated with sulfasalazine
Gupta	1986	Therapy of AIDS and AIDS-related syndromes
WO1989009056A1 (fr)	1989-10-05	Composition antivirale contenant des diones aromatiques polycycliques et des analogues de nucleosides, et procede de traitement d'infections retrovirales
JPS63107924A (ja)	1988-05-12	抗レトロウイルス剤
JP2990015B2 (ja)	1999-12-13	抗ｈｉｖ剤